Business

mass. movers

Agenus finalizes European acquisition

Associated Press/File 2010

Advertisement

Lexington-based Agenus Inc., which is developing novel immunotherapeutics, including anti-cancer vaccines, completed its acquisition of 4-Antibody AG, a private European biopharmaceutical company. Agenus acquired all outstanding stock of 4-Antibody for about 3.3 million shares of Agenus common stock, plus additional contingent payments that may exceed $40 million based on the combined company achieving certain milestones. Agenus intends to continue 4-Antibody’s operations in Basel, Switzerland, and Jena, Germany.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.